publication date: May. 15, 2015

ASCO Annual Meeting 2015: Highlights of Selected Studies


The American Society of Clinical Oncology announced results from four major studies May 13, which will be presented at the society’s 51st Annual Meeting, May 29 to June 2, in Chicago.

The studies are:

• A large Australian trial showing that daily use of nicotinamide, a form of vitamin B3, for 12 months reduced the incidence of new non-melanoma skin cancers by 23 percent in patients at high risk for skin cancer.

• A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months.

• Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen.

• A large trial showing that men with newly diagnosed, advanced prostate cancer lived ten months longer, on average, when they received docetaxel chemotherapy along with standard hormone therapy.

These studies are among the 5,000 abstracts publicly released in advance of the meeting.

Other major research, including studies selected for the meeting’s Plenary Session, will be released as Late-Breaking Abstracts on-site at Chicago’s McCormick Place and online on a rolling basis throughout the meeting. Around 25,000 oncology professionals are expected at the meeting, which focuses on the theme Illumination and Innovation.

“Trials like these are engines of progress for … Continue reading 41-19 ASCO Annual Meeting 2015: Highlights of Selected Studies

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.